http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103126993-B

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d64d39317a5cfb46f5c0bde6569f677a
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
filingDate 2011-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2015-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9363085419c23b548656755814a882e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_904ab195cf0f90cf5e1b7d220ad16342
publicationDate 2015-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-103126993-B
titleOfInvention Tumor cell active targeting drug delivery system based on nanometer particles and construction method thereof
abstract The invention relates to a tumor cell active targeting drug delivery system based on nanometer particles and a construction method thereof. The tumor cell active targeting drug delivery system is characterized by using the nanometer particles with photocatalytic performance as carriers to obtain targeted molecule/nanometer particle/chemotherapy drug compounds in a physical absorption or chemical bonding mode, the mole ratio of the nanometer particles and targeted molecules is 50:1-20:1, the mole ratio of the nanometer particles and chemotherapy drugs is 50:1-10:1. The tumor cell active targeting drug delivery system integrates the chemotherapy drugs, the targeted molecules and the nanometers particles with photocatalytic performance, enables a nanometer particle dry carrying system to have active tumor cell targeting capacity, effectively reduces side effects of the chemotherapy drugs, can realize controllable release of the chemotherapy drug and reverse multiple drug resistance of the tumor cell, and is simple and easy in construction method, low in cost, and favorable to industrialized production and market popularization.
priorityDate 2011-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419579548
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31703
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID947
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID62395
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457707770
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535365
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419552576
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398658
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4112
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID126941
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11296583
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419504051
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID41867
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457707785
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426366935
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419556970
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419582859
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID42890
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507158
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID26042
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1464
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419493376
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID169371
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419552499

Total number of triples: 41.